LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Iovance Biotherapeutics Inc

Затворен

СекторЗдравеопазване

1.75 -3.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.75

Максимум

1.77

Ключови измерители

By Trading Economics

Приходи

-38M

-116M

Продажби

-24M

49M

EPS

-0.36

Марж на печалбата

-235.51

Служители

838

EBITDA

-35M

-110M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+555.74% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-574M

594M

Предишно отваряне

5.06

Предишно затваряне

1.75

Настроения в новините

By Acuity

50%

50%

151 / 381 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Iovance Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.05.2025 г., 10:30 ч. UTC

Топ новини

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31.05.2025 г., 06:30 ч. UTC

Печалби

5 Things We've Learned From Retail Earnings -- Barrons.com

31.05.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 23:51 ч. UTC

Придобивния, сливания и поглъщания

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30.05.2025 г., 21:30 ч. UTC

Топ новини

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30.05.2025 г., 21:15 ч. UTC

Топ новини

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30.05.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

30.05.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30.05.2025 г., 20:24 ч. UTC

Топ новини

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30.05.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 19:44 ч. UTC

Пазарно говорене

Gold Breaks 4-Month Winning Streak -- Market Talk

30.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30.05.2025 г., 19:29 ч. UTC

Печалби
Придобивния, сливания и поглъщания

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30.05.2025 г., 19:14 ч. UTC

Пазарно говорене

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30.05.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30.05.2025 г., 18:51 ч. UTC

Пазарно говорене

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30.05.2025 г., 18:37 ч. UTC

Пазарно говорене
Печалби

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30.05.2025 г., 18:04 ч. UTC

Топ новини

S&P 500 Falls After More Trump-China Friction -- WSJ

30.05.2025 г., 17:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.05.2025 г., 17:47 ч. UTC

Пазарно говорене

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30.05.2025 г., 17:40 ч. UTC

Придобивния, сливания и поглъщания

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30.05.2025 г., 17:38 ч. UTC

Пазарно говорене

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30.05.2025 г., 17:31 ч. UTC

Пазарно говорене

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30.05.2025 г., 17:14 ч. UTC

Топ новини

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30.05.2025 г., 16:31 ч. UTC

Печалби

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30.05.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

30.05.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

30.05.2025 г., 16:16 ч. UTC

Топ новини

S&P 500 Falls After Trump Hits Out at China -- WSJ

30.05.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 16:14 ч. UTC

Топ новини

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Iovance Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

555.74% нагоре

12-месечна прогноза

Среден 12 USD  555.74%

Висок 25 USD

Нисък 2 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Iovance Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

9

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

3.0208 / 3.5Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

151 / 381 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.